Vol 48 No 7

"This new therapy could change the landscape for the treatment of advanced prostate cancer," Thrasher writes.

Oral GnRH receptor antagonist has “potential to become a new standard for ADT,” a study investigator says.

The study compared regimens for patients with high-risk non–muscle invasive bladder cancer.

Significant improvements in BPH-related lower urinary tract symptoms were observed with the system.

72.9% of patients with papillary disease achieved high-grade recurrence-free survival at 3 months after initial treatment.

3 urologists discuss their experience with telemedicine during the COVID-19 pandemic.

Withdrawals from pretax retirement accounts are among the ways to bridge your income, according to Jeff Witz, CFP.

Samuel J. Peretsman, MD, discusses which patients with prostate cancer can be treated with HIFU, contraindications to the treatment, and what expectations patients need to have postoperatively.

Dr. Badar M. Mian highlights the safety and efficacy of relugolix, describing the drug as an “exciting new option” for patients with recurrent or advanced prostate cancer.

The decline in total testosterone was observed even among men with normal body mass index.

The reduction in urinary urgency incontinence episodes observed was “quite significant,” an investigator said.

The deletion of code 99201 is among the evaluation/management coding changes for 2021.

Only 1.5% of patients undergo repeat surgical intervention for BPH recurrence.